NETwork of Linoleic Acid Supplementation in Cystic Fibrosis

Plain-language summary

This study compared linoleic acid supplementation with oleic acid supplementation in people with cystic fibrosis. It enrolled patients carrying two mutations associated with severe clinical status, such as dF508, along with pancreatic insufficiency. This is a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Karolinska Institutet

Intervention

linoleic acid supplementation, oleic acid supplementation

Start date

10/25/2021

Estimated completion

11/5/2024

Countries

Italy, Norway, Poland

Related genes

Locations

• Milan, Italy
• Oslo, Norway
• Poznan, Poland

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Two mutations related to severe clinical status such as dF508, or other stop mutations or class II mutations. Severe status includes pancreatic insufficiency

Exclusion Criteria:

* Liver cirrhosis and/or portal hypertension, transplantation or on transplantation list, intake of lipid supplements the latest 2 months